Precision BioSciences Past Earnings Performance
Past criteria checks 0/6
Precision BioSciences has been growing earnings at an average annual rate of 1.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 19.1% per year.
Key information
1.8%
Earnings growth rate
35.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 19.1% |
Return on equity | -225.5% |
Net Margin | -87.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
Aug 06It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks
Jun 23Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?
Mar 14Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?
Dec 08Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles
Sep 02Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash
Aug 16Precision BioSciences Q2 2022 Earnings Preview
Aug 05Precision Bio: Another CAR-T Laggard With No Solid Prospects
May 09Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt
Apr 19Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)
Mar 21Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely
Dec 31Precision BioSciences: Uniquely Positioned
Oct 07Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?
Sep 24Precision BioSciences: The Right Profile To Progress
Aug 27Revenue & Expenses BreakdownBeta
How Precision BioSciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 49 | -43 | 41 | 51 |
30 Sep 23 | 52 | -87 | 44 | 87 |
30 Jun 23 | 47 | -89 | 44 | 82 |
31 Mar 23 | 31 | -109 | 45 | 83 |
31 Dec 22 | 25 | -73 | 43 | 44 |
30 Sep 22 | 21 | -76 | 47 | 55 |
30 Jun 22 | 38 | -93 | 44 | 92 |
31 Mar 22 | 102 | -40 | 44 | 106 |
31 Dec 21 | 116 | -31 | 43 | 112 |
30 Sep 21 | 118 | -32 | 42 | 109 |
30 Jun 21 | 101 | -47 | 42 | 106 |
31 Mar 21 | 34 | -101 | 40 | 95 |
31 Dec 20 | 24 | -109 | 39 | 95 |
30 Sep 20 | 22 | -106 | 38 | 92 |
30 Jun 20 | 19 | -101 | 37 | 87 |
31 Mar 20 | 24 | -88 | 35 | 84 |
31 Dec 19 | 22 | -93 | 30 | 79 |
30 Sep 19 | 21 | -87 | 25 | 77 |
30 Jun 19 | 18 | -76 | 21 | 67 |
31 Mar 19 | 15 | -69 | 17 | 56 |
31 Dec 18 | 11 | -46 | 15 | 44 |
30 Sep 18 | 7 | -38 | 12 | 35 |
31 Dec 17 | 6 | -21 | 9 | 19 |
31 Dec 16 | 7 | -8 | 7 | 9 |
Quality Earnings: DTIL is currently unprofitable.
Growing Profit Margin: DTIL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DTIL is unprofitable, but has reduced losses over the past 5 years at a rate of 1.8% per year.
Accelerating Growth: Unable to compare DTIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DTIL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: DTIL has a negative Return on Equity (-225.48%), as it is currently unprofitable.